论文部分内容阅读
目的探讨阿斯美对慢性阻塞性肺病的治疗作用,关注治疗后血清中超敏C反应蛋白(hs-CRP)的变化,以积累经验,指导临床诊疗。方法收集在我院确诊的146例慢性阻塞性肺病患者,依患者的入院顺序分为观察组和对照组,观察组(73例)在常规治疗基础上加用阿斯美,对照组(73例)在常规治疗基础上加用氨茶碱,观察治疗的疗效及对血清中hs-CRP调节作用。结果阿斯美治疗组在改善FEV1及血气分析指标方面均优于氨茶碱治疗组,且观察组对血清中hs-CRP的改变值明显高于对照组。结论慢性阻塞性肺病患者在常规治疗基础上加用阿斯美治疗,临床疗效明显,且能对血清中hs-CRP的表达具有下调作用,临床治疗中可以积极应用。
Objective To investigate the therapeutic effect of Asme on chronic obstructive pulmonary disease (COPD) and to observe the changes of serum hs-CRP after treatment in order to accumulate experience and guide the clinical diagnosis and treatment. Methods A total of 146 patients with chronic obstructive pulmonary disease (COPD) diagnosed in our hospital were collected and divided into observation group and control group according to the admission order of the patients. The observation group (73 cases) ) On the basis of conventional treatment with aminophylline to observe the therapeutic effect and serum hs-CRP regulatory effect. Results Asimi treatment group was better than aminophylline treatment group in improving FEV1 and blood gas analysis indexes, and the changes of serum hs-CRP in the observation group were significantly higher than those in the control group. Conclusions Aspirin can be used in patients with chronic obstructive pulmonary disease on the basis of routine treatment. The clinical curative effect is obvious, and the expression of hs-CRP in serum can be down-regulated. It can be actively used in clinical treatment.